Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 504

1.

Sodium-dependent glucose transporters (SGLT) in human ischemic heart: A new potential pharmacological target.

Di Franco A, Cantini G, Tani A, Coppini R, Zecchi-Orlandini S, Raimondi L, Luconi M, Mannucci E.

Int J Cardiol. 2017 May 9. pii: S0167-5273(16)34166-3. doi: 10.1016/j.ijcard.2017.05.032. [Epub ahead of print]

PMID:
28526540
2.

Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.

Paneni F, Lüscher TF.

Am J Med. 2017 May 15. pii: S0002-9343(17)30467-9. doi: 10.1016/j.amjmed.2017.04.008. [Epub ahead of print]

PMID:
28526186
3.

EMPA-REG OUTCOME: The Endocrinologist's Point of View.

Perreault L.

Am J Med. 2017 May 12. pii: S0002-9343(17)30458-8. doi: 10.1016/j.amjmed.2017.04.005. [Epub ahead of print]

PMID:
28526185
4.

Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms.

Staels B.

Am J Med. 2017 May 15. pii: S0002-9343(17)30468-0. doi: 10.1016/j.amjmed.2017.04.009. [Epub ahead of print]

PMID:
28526184
5.

Diabetes Mellitus and Heart Failure.

Lehrke M, Marx N.

Am J Med. 2017 May 15. pii: S0002-9343(17)30469-2. doi: 10.1016/j.amjmed.2017.04.010. [Epub ahead of print]

PMID:
28526183
6.

Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.

Thrasher J.

Am J Med. 2017 May 12. pii: S0002-9343(17)30457-6. doi: 10.1016/j.amjmed.2017.04.004. [Epub ahead of print]

PMID:
28526182
7.

EMPA-REG OUTCOME: The Cardiologist's Point of View.

Pham SV, Chilton R.

Am J Med. 2017 May 15. pii: S0002-9343(17)30459-X. doi: 10.1016/j.amjmed.2017.04.006. [Epub ahead of print]

PMID:
28526181
8.

Introduction.

Chilton R.

Am J Med. 2017 May 12. pii: S0002-9343(17)30456-4. doi: 10.1016/j.amjmed.2017.04.003. [Epub ahead of print] No abstract available.

PMID:
28526180
9.

EMPA-REG OUTCOME: The Nephrologist's Point of View.

Wanner C.

Am J Med. 2017 May 16. pii: S0002-9343(17)30460-6. doi: 10.1016/j.amjmed.2017.04.007. [Epub ahead of print]

PMID:
28526179
10.

Lower Risk of Heart Failure and Death in Patients Initiated on SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study.

Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Birkeland KI, Jørgensen M, Thuresson M, Arya N, Bodegård J, Hammar N, Fenici P; CVD-REAL Investigators and Study Group..

Circulation. 2017 May 18. pii: CIRCULATIONAHA.117.029190. doi: 10.1161/CIRCULATIONAHA.117.029190. [Epub ahead of print]

PMID:
28522450
11.

Impact of glucose-lowering therapies on risk of stroke in type 2 diabetes.

Bonnet F, Scheen AJ.

Diabetes Metab. 2017 May 15. pii: S1262-3636(17)30075-7. doi: 10.1016/j.diabet.2017.04.004. [Epub ahead of print] Review.

PMID:
28522196
12.

[Cardiovascular Effects of Antidiabetic Therapies].

Laubner K, Seufert J.

Dtsch Med Wochenschr. 2017 May;142(10):737-745. doi: 10.1055/s-0043-100564. Epub 2017 May 17. German.

PMID:
28514822
13.

Characterization and comparison of SGLT2 inhibitors: Part 3. Effects on diabetic complications in type 2 diabetic mice.

Tahara A, Takasu T, Yokono M, Imamura M, Kurosaki E.

Eur J Pharmacol. 2017 May 12. pii: S0014-2999(17)30338-2. doi: 10.1016/j.ejphar.2017.05.019. [Epub ahead of print]

PMID:
28506912
14.

Differential cardiovascular profiles of sodium-glucose cotransporter 2 inhibitors: critical evaluation of empagliflozin.

Sanon VP, Patel S, Sanon S, Rodriguez R, Pham SV, Chilton R.

Ther Clin Risk Manag. 2017 May 3;13:603-611. doi: 10.2147/TCRM.S97619. eCollection 2017. Review.

15.

The effect of empagliflozin on oxidative nucleic acid modifications in patients with type 2 diabetes: protocol for a randomised, double-blinded, placebo-controlled trial.

Larsen EL, Cejvanovic V, Kjær LK, Vilsbøll T, Knop FK, Rungby J, Poulsen HE.

BMJ Open. 2017 May 9;7(5):e014728. doi: 10.1136/bmjopen-2016-014728.

16.

Cardiovascular safety outcomes of new antidiabetic therapies.

LeBras MH, Barry AR, Koshman SL.

Am J Health Syst Pharm. 2017 May 8. pii: e285. doi: 10.2146/ajhp160279. [Epub ahead of print]

PMID:
28483748
17.
18.

Efficacy and Safety of Single-Drug or Double-Drug Antidiabetic Regimens in the Treatment of Type 2 Diabetes Mellitus: A Network Meta-Analysis.

Yang XL, Duo-Ji MM, Long ZW.

J Cell Biochem. 2017 May 4. doi: 10.1002/jcb.26115. [Epub ahead of print]

PMID:
28471499
19.
20.

Promising cardiovascular and blood pressure effects of the SGLT2 inhibitors: a new class of antidiabetic drugs.

Chrysant SG.

Drugs Today (Barc). 2017 Mar;53(3):191-202. doi: 10.1358/dot.2017.53.3.2555985.

PMID:
28447076

Supplemental Content

Loading ...
Support Center